PDCD1 and melanoma: Recently, there have been significant advancements in therapies for treating stage III and IV melanomas, including targeting molecular pathways using BRAF and MEK inhibitors or immune checkpoint inhibitors, such as PD-1, CTLA-4, or LAG-3 inhibitors [6,18,30,36,40,41,42,43,44,45,46,47,48].